Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Fy26 Premiums topic
No spam. Unsubscribe anytime.
GIC briefed on 10.5% preliminary FY26 premium increase; consultants and CFO warn GLP‑1 drug spending and provider pricing are driving budget pressure
Summary
Consultants from WTW told the Group Insurance Commission that a status‑quo, preliminary FY26 full‑cost premium increase is about 10.5%, largely driven by GLP‑1 drug uptake; the CFO reported the GIC is roughly $100 million over budget through November and staff are coordinating with Administration & Finance on funding options.
Consultants from Willis Towers Watson (WTW) told the Group Insurance Commission that, on a status‑quo basis with no plan‑design changes, the GIC faces a preliminary aggregate FY26 premium increase of "around 10 a half percent," driven by rising unit costs, utilization and rapid growth in GLP‑1 drug use for diabetes and obesity.
"This is our status quo estimate…an initial expected increase of around 10 a half percent for FY 26," the WTW presenter said, noting the projection covers both non‑Medicare and Medicare plans and that plan‑level impacts will vary.
WTW highlighted GLP‑1 drugs as a central cost driver: use in the active population doubled for diabetes indications and increased roughly tenfold for obesity indications in recent years. Presenters said the drugs are clinically valuable but expensive; staff reported "the costs after rebates and discounts are about $9,000 a year" per patient for newer GLP‑1 treatments.
Consultants explained that while GLP‑1s can provide important health benefits, they are "cost‑effective" rather than cost‑saving — meaning clinical gains do not necessarily offset the drug price in reduced medical spending. WTW also cited other upward pressures: negotiated unit‑cost increases with providers, hospital contract renewals and behavioral‑health demand.
CFO Jim Rust told the commission that through November FY25 spending was "a $100,000,000 over budget," roughly 9% of year‑to‑date spend, and that staff are working with Administration & Finance on options to address the shortfall, which could include supplemental appropriation or other funding sources. In response to a question about scale, WTW estimated projected total claims (medical, pharmacy and admin) at "roughly $3,900,000,000" on a before‑contributions basis for the projection.
Commissioners discussed equity and access — noting patterns of differential GLP‑1 uptake tied to geography and socioeconomic status — and pressed staff to prioritize network continuity, primary care investment and targeted use of therapies where value is highest. Staff said the commission will continue the rate‑setting calendar (public information sessions in January, plan‑design votes in February and final rates in late February) and will reforecast GLP‑1 spend as new data emerge.
Next steps: WTW will refine trend assumptions and GLP‑1 forecasts; GIC staff will present plan‑design proposals and updated rate scenarios in January/February and continue monthly FY25 budget updates to the commission.
